AbbVie says MAVYRET shows high virologic cure rates in treatment-naive HCV.
AbbVie announced new data for its pan-genotypic chronic hepatitis C virus treatment, MAVYRET, in treatment-naive patients with compensated cirrhosis. Results from the Phase 3b EXPEDITION-8 study showed that with 8 weeks of MAVYRET, 100 percent of genotype 1, 2, 4, 5 and 6 patients achieved a sustained virologic response 12 weeks after treatment per protocol analysis. This analysis is part of the ongoing Phase 3b EXPEDITION-8 study evaluating the safety and efficacy of MAVYRET in treatment-naive chronic HCV patients with compensated cirrhosis across all major genotypes. The study includes two cohorts; cohort one with genotype 1, 2, 4, 5, 6 chronic HCV-infected patients, and cohort two with genotype 3 chronic HCV-infected patients. To date, no virologic failures have been reported in cohort one of the study and no patients have discontinued treatment due to adverse events. Adverse events reported of the study populations include pruritus, fatigue, headache and nausea. Six serious adverse events have occurred during the study, none of which were deemed to be related to glecaprevir/pibrentasvir. No new safety signals were identified in this study.
|Printer friendly Cite/link Email Feedback|
|Article Type:||Clinical report|
|Date:||Nov 13, 2018|
|Previous Article:||PlayerUnknown's Battlegrounds, coming to PS4 next month.|
|Next Article:||Microsoft, Nielsen announce strategic alliance for retail innovation.|